A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety and efficacy in subjects with moderate to severe
psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA),
Dermatology Life Quality Index (DLQI) and other assessments.
Phase:
Phase 2
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics